Check-Cap (NASDAQ: CHEK) stock is heading higher on Monday after the company announced approval from the U.S. Food and Drug Administration (FDA) for one of its devices. Source: Shutterstock According to the company, the FDA has appvoed its Investigational Device Exemption (IDE) application for C-Scan.
Full Answer
Who bought Chek stock?
CHEK stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., UBS Group AG, and Two Sigma Securities LLC. How do I buy shares of Check-Cap?
How can I get the latest news about Chek?
Sign up to receive the latest news and ratings for CHEK and its competitors with MarketBeat's FREE daily newsletter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Why has check cap’s stock price increased 130% pre-market?
The stock price of Check Cap Ltd (NASDAQ: CHEK) – a clinical stage medical diagnostics company advancing the development of C-Scan, the first and only patient-friendly, preparation-free, screening test to detect polyps before they may transform into colorectal cancer (CRC) – has increased by over 130% pre-market.
Did check-cap insiders sell or buy the stock?
In the past three months, Check-Cap insiders have not sold or bought any company stock. Only 18.39% of the stock of Check-Cap is held by institutions. Earnings for Check-Cap are expected to grow in the coming year, from ($0.20) to ($0.17) per share.
Will CHEK stock go up?
Check Cap Ltd (NASDAQ:CHEK) The 2 analysts offering 12-month price forecasts for Check Cap Ltd have a median target of 2.00, with a high estimate of 3.00 and a low estimate of 1.00. The median estimate represents a +452.18% increase from the last price of 0.36.
Is CHEK a good buy?
Out of 1 analyst, 0 (0%) are recommending CHEK as a Strong Buy, 1 (100%) are recommending CHEK as a Buy, 0 (0%) are recommending CHEK as a Hold, 0 (0%) are recommending CHEK as a Sell, and 0 (0%) are recommending CHEK as a Strong Sell. What is CHEK's earnings growth forecast for 2022-2024?
How do I check a stock price?
The 10 Best Ways to Check Stock Prices OnlineMarketWatch.CNN Markets.U.S News.Google Finance.Investopedia.6. Yahoo! Finance.Stocks (Mac)Nasdaq.More items...•
Will Check-Cap get FDA approval?
The FDA has granted investigational device exemption to medical diagnostics company Check-Cap for a two-part pivotal study to evaluate C-Scan, a new screening test that detects precancerous polyps.
Which stock is best to buy now?
Hold Voltas, target price Rs 1033: ICICI Securities. ... Buy Housing Development Finance Corporation, target price Rs 3205: ICICI Securities. ... Buy State Bank of India, target price Rs 673: ICICI Securities. ... Buy Bharat Electronics, target price Rs 275: Axis Securities. ... Buy NHPC, target price Rs 40: Emkay Global.More items...
Which is best stocks to invest?
These stocks are suitable for both the bottom-up and top-down approaches to investing....Best Stocks to Invest in 2022.S.No.Top Stocks1.Reliance Industries2.Tata Consultancy Services3.HDFC Bank4.Infosys1 more row•Jun 8, 2022
What is the 5G master key?
The promise this time is that a small company possesses the “Master Key” technology for 5G, enabling it to solve 5G's well-known problems (like, the fact that some of the wavelengths used mean the signals can't get through walls, or even windows or leaves)… and the fella making the promise is E.B.
Is Check-Cap a buy right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Check-Cap in the last year. There are currently 2 buy ratings for the stoc...
Are investors shorting Check-Cap?
Check-Cap saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,360,000 shares, a decline of 24....
When is Check-Cap's next earnings date?
Check-Cap is scheduled to release its next quarterly earnings announcement on Wednesday, June 1st 2022. View our earnings forecast for Check-Cap .
How were Check-Cap's earnings last quarter?
Check-Cap Ltd. (NASDAQ:CHEK) posted its quarterly earnings data on Thursday, April, 7th. The medical research company reported ($0.06) earnings per...
When did Check-Cap's stock split? How did Check-Cap's stock split work?
Shares of Check-Cap reverse split on the morning of Wednesday, April 4th 2018. The 1-12 reverse split was announced on Wednesday, April 4th 2018. T...
What price target have analysts set for CHEK?
2 analysts have issued 12 month target prices for Check-Cap's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Check-...
Who are Check-Cap's key executives?
Check-Cap's management team includes the following people: Mr. Alex Ovadia , CEO & Director (Age 60, Pay $493.56k) Dr. Yoav Kimchy Ph.D. , Foun...
Who are some of Check-Cap's key competitors?
Some companies that are related to Check-Cap include Ampliphi Biosciences (APHB) , ObsEva (OBSV) , Retractable Technologies (RVP) , Retractable...
What other stocks do shareholders of Check-Cap own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Check-Cap investors own include Alibaba Group (BABA) , Na...
How many shares of check cap stock are there after the split?
The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 3rd 2018. An investor that had 100 shares of Check-Cap stock prior to the reverse split would have 8 shares after the split.
When will check cap earnings be released?
Check-Cap is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Check-Cap.
Who is the CEO of Check Cap?
Alex Ovadia, CEO of Check-Cap, said this about the news boosting CHEK stock up today. “The IDE approval is a significant milestone for Check-Cap.
When will check cap be released in 2021?
March 15, 2021. Check-Cap (NASDAQ: CHEK) stock is heading higher on Monday after the company announced approval from the U.S. Food and Drug Administration (FDA) for one of its devices. Source: Shutterstock. According to the company, the FDA has appvoed its Investigational Device Exemption (IDE) application for C-Scan.
Recently Viewed Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
Check-Cap Ltd
Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer.
Check-Cap Issues Letter to Shareholders
Check-Cap Ltd.
Companies Like Check-Cap (NASDAQ:CHEK) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
How Long Is Check-Cap's Cash Runway?
A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2020, Check-Cap had cash of US$21m and no debt. Importantly, its cash burn was US$13m over the trailing twelve months. Therefore, from September 2020 it had roughly 19 months of cash runway.
How Is Check-Cap's Cash Burn Changing Over Time?
Because Check-Cap isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time.